Two-Year Clinical Results Reinforce Long-Term Effectiveness of MyoPro® Lens

Tuesday, November 11 2025 | 08 h 05 min | News

Newly published two-year clinical data in Investigative Ophthalmology & Visual Science (IOVS) confirm that the MyoPro® Defocus Lens continues to slow myopia progression in children over extended wear.

The findings, now indexed on PubMed, provide additional scientific support for defocus-based spectacle lens options as part of long-term myopia management strategies. The results come from a randomized, double-blind clinical trial conducted at Wenzhou Medical University in China, following children over a 24-month period. The study compared MyoPro® lenses with standard single-vision lenses, assessing changes in refractive error and axial elongation.

According to the published data, MyoPro® lenses maintained a consistent myopia-control effect throughout the two years of follow-up without adverse adaptation concerns or reductions in visual acuity.

“This new two-year data provides powerful clinical evidence that MyoPro® continues to deliver measurable, lasting benefits for children with myopia,” said Olive Su, General Manager of East Optical. “It further strengthens our commitment to supporting independent eye care professionals with scientifically proven technology that’s shaping the future of vision care.”

A Closer Look at the Findings

The study reports that MyoPro® lenses slowed myopia progression by 67% on average, including an 81.2% reduction in the 10–12 age group. Axial elongation was reduced by 50% compared with single-vision controls. Importantly, the two-year extension results show that this effect did not diminish over time, addressing a common concern regarding the long-term efficacy of optical interventions.

Participants across a range of baseline prescriptions demonstrated similar patterns of slowed progression, suggesting that the lens design may have applicability across different patient profiles. Researchers also noted that visual performance remained stable, with no indication of compromised acuity or symptoms associated with defocus-based optical designs.

About the Journal and Scientific Credibility

Investigative Ophthalmology & Visual Science (IOVS) is one of the most widely recognized journals in the vision science and clinical eye research community. It is the flagship peer-reviewed publication of the Association for Research in Vision and Ophthalmology (ARVO), the world’s largest eye and vision research organization. ARVO represents more than 10,000 researchers across 75 countries, and studies accepted into IOVS undergo rigorous scientific and methodological review.

Publication in IOVS generally signals that a study meets high standards for clinical evidence, study design, statistical analysis, and relevance to current scientific understanding. For eye care professionals evaluating myopia management options, the inclusion of this trial in such a reputable journal adds meaningful weight to its findings.